KRAS and neoplasm: We describe an approach to robustly inflame the TME of KRAS-dependent cancers by combining an ASO against the mutated KRAS (KRAS ASO) and immRNA to simultaneously suppress the KRAS mutant and activate the RIG-I pathway in tumor cells, respectively.